Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Walvax PCV13 in Healthy Infants and Toddlers
NCT02736240Phase 3Completed
- Sponsor
- Walvax Biotechnology Co., Ltd.
- Start
- Apr 2016
- Primary completion
- Dec 2017
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, double-blind trial of 13-valent pneumococcal polysaccharide conjugate vaccine in pneumococcal disease (2 arms), sponsored by Walvax Biotechnology Co., Ltd. Primary endpoints: Positive rate after infant doses, Geometric Mean Concentration after infant doses and 2 more. Started Apr 2016; status: completed.
02
Drugs
13-valent pneumococcal polysaccharide conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT02736240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02736240.